Vascular Protection

Arteriosclerosis, Thrombosis, and Vascular Biology - Tập 20 Số 6 - Trang 1512-1520 - 2000
Ian Zachary1, Anthony Mathur1, Seppo Ylä‐Herttuala1, John F. Martin1
1From the Department of Medicine (I.Z., A.M., J.M.), University College London, London, UK, and A.I. Virtanen Institute and Department of Medicine (S.Y.-H.), University of Kuopio, Kuopio, Finland.

Tóm tắt

Abstract —There is widespread interest in the use of the angiogenic cytokine, vascular endothelial growth factor (VEGF), for the treatment of cardiovascular disease. The main paradigm for VEGF cardiovascular therapy is the stimulation of “therapeutic angiogenesis” in ischemic myocardial and peripheral vascular limb disease. In this review, approaches to VEGF therapy based on the therapeutic angiogenesis model are critically assessed, and the alternative mechanism of vascular protection is advanced. Vascular protection is defined as the VEGF-induced enhancement of endothelial functions that mediate the inhibition of vascular smooth muscle cell proliferation, enhanced endothelial cell survival, suppression of thrombosis, and anti-inflammatory effects. VEGF-induced synthesis of NO and prostacyclin are both likely to be key mediators of VEGF-dependent vascular protection. Investigation into vascular protection should help us to gain insight into the underlying mechanisms of the cardiovascular actions of VEGF and should prove valuable in the development of novel therapeutic approaches based on local VEGF gene delivery.

Từ khóa


Tài liệu tham khảo

Ferrara N. Vascular endothelial growth factor. Eur J Cancer . 1996;32A:2413–2422.

10.1038/386671a0

10.1038/nm0195-27

10.1161/atvb.17.4.605

10.1038/8374

10.1001/archsurg.1993.01420160061009

10.1038/nm0596-519

10.1016/S0008-6363(98)00293-4

10.1161/circ.91.11.2793

10.1161/circ.94.12.3291

10.1161/circ.95.2.438

10.1016/S0735-1097(97)00049-1

10.1172/JCI117018

10.1161/circ.89.5.7514110

10.1038/nm1095-1085

10.1161/circ.91.11.2802

10.1016/S0741-5214(95)70272-5

10.1097/00005344-199601000-00015

1996, Am J Physiol, 270, H1791

10.1006/jsre.1996.0226

10.1016/S0008-6363(98)00136-9

10.1016/S0022-5223(98)70455-6

10.1253/jcj.62.933

10.1016/S0741-5214(98)70304-0

10.1016/S0140-6736(96)03361-2

10.1161/circ.97.12.1114

10.1161/circ.97.7.645

10.1161/circ.98.25.2800

10.1126/science.275.5302.964

10.1172/JCI6889

10.1093/emboj/18.14.3964

10.1161/circ.99.13.1653

10.1002/path.1700630204

10.1172/JCI1568

10.1161/res.62.3.3342475

10.1161/circ.99.13.1726

10.1161/circ.94.5.1074

10.1161/circ.94.8.1927

10.1016/0006-291X(92)92277-5

Asahara T Bauters C Zheng LP Takeshita S Bunting S Ferrara N Symes JF Isner JM. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation . 1995;92(suppl II):II-365–II-371.

10.1161/res.80.6.829

1997, J Clin Invest, 101, 40

10.1074/jbc.271.30.17629

10.1126/science.277.5323.242

1999, J Am Coll Cardiol, 33, 384A

Laitinen M Hartikainen J Eranen J Kivinemi M Hiltunen MO Laakso M Yla-Herttuala S. Catheter-mediated gene transfer to human coronary arteries after angioplasty: safety results from phase I Kuopio Angioplasty Gene Transfer Trial (KAT Trial). Circulation . 1998;98(suppl I):I-322. Abstract.

10.1089/10430340050016003

10.1152/ajpheart.1993.265.2.H586

10.1161/atvb.17.11.2793

10.1084/jem.172.6.1535

10.1016/S0021-9258(19)47212-8

10.1016/0021-9150(89)90109-3

10.1161/atv91.13.4.8466892

10.1089/hum.1997.8.14-1645

10.1089/hum.1997.8.15-1737

10.1161/circ.95.4.1030

10.1038/nm0897-879

10.1016/S0014-5793(97)01481-6

10.1161/circ.97.1.99

10.3171/jns.1989.71.6.0884

10.1152/ajpcell.1997.273.2.C687

10.1038/33934

10.1172/JCI114081

10.1073/pnas.92.4.1137

10.1016/0952-3278(94)90187-2

10.1042/bj2880527

10.1038/sj.onc.1201038

10.1042/bj3420407

10.1136/hrt.71.1.7

10.1056/NEJM199602013340504

10.1161/atvb.19.3.727

10.1161/circ.98.9.919

10.1016/0090-6980(78)90216-2

10.1016/0092-8674(94)90267-4

10.1016/0006-291X(91)91276-I

1991, Am J Pathol, 138, 213

10.1096/fasebj.7.2.8440408

10.1182/blood.V71.1.1.1

10.1161/atvb.19.3.531

10.1038/383073a0

10.1016/S1050-1738(96)00142-9

10.1083/jcb.109.1.367

10.1073/pnas.94.2.663

10.1055/s-0037-1615158

10.1161/atvb.19.7.1757

10.1073/pnas.88.11.4651

10.1172/JCI118074

10.1016/S0008-6363(98)00228-4

10.1152/ajpheart.1998.274.3.H1054

10.1038/nm1095-1024

10.1074/jbc.273.46.30336

10.1074/jbc.274.15.10002

10.1074/jbc.272.24.15442

10.1083/jcb.143.2.547

10.1084/jem.187.4.579

10.1083/jcb.134.3.793

10.1074/jbc.274.19.13328

10.1016/S0021-9258(18)47116-5

10.1096/fasebj.13.1.9

10.1016/S0092-8674(00)81402-6

10.1073/pnas.93.6.2576

10.1126/science.276.5317.1423

10.1073/pnas.95.2.548

10.1016/S0002-9440(10)65582-4

10.1016/0014-5793(94)01458-D

10.1161/circ.92.1.5

10.1161/circ.90.2.8044933

10.1161/atvb.18.7.1188

10.1161/atvb.19.1.131

10.1097/00041433-199704000-00004

10.1074/jbc.272.3.1747

10.1152/ajpcell.1999.276.6.C1271

10.1172/JCI119451

1994, Am J Physiol, 267, H1263

1995, Am J Pathol, 147, 1649

Takeshita S Pu LQ Stein LA Sniderman AD Bunting S Ferrara N Isner JM Symes JF. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation . 1994;90(suppl II):II-228–II-234.

10.1016/S0741-5214(98)70269-1

10.1006/bbrc.1996.1556

10.1161/circ.98.13.1261

10.1016/S0741-5214(98)70022-9

Thông tin
Thông tin xuất bản

Arteriosclerosis, Thrombosis, and Vascular Biology

Tập 20 Số 6

1512-1520

Thông tin tác giả